LL-37 Dosage Calculator & Research Doses

1Set Up Your Mix

1.667 mg/mL · 1667 mcg/mL

1. Pick your peptide

2. How much peptide is in the vial? It's printed on the label — usually something like 5 mg

3. How much water are you adding? More water makes each dose easier to measure

4. How much do you want per dose?

Your Answer — LL-37

5 mg in 3 mL

6Draw To This Line

0.06That's This Many mL

50Doses In The Vial

5 mg ÷ 3 mL = 1.667 mg/mL → 100 mcg ÷ 1.667 mg/mL = 0.06 mL → × 100 = 6 units

Looks good. Draw to 6 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 50 doses.

When to dose

Time of dayNo particular time of day has been established.

FoodNo fasting requirement has been established.

The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.

2Week-By-Week Plan — LL-37

Start low, work up

When	Dose	How Often	How Many mL	Draw To	Number Of Doses	Peptide Used
Weeks 1–2	100 mcg	daily	0.06 mL	6 u	14	1.4 mg
Weeks 3–4	250 mcg	daily	0.15 mL	15 u	14	3.5 mg
Week 5 onward per 4 weeks from here on	500 mcg	daily	0.3 mL	30 u	28	14 mg

Time until the top dose

4 weeks

Peptide used getting there

4.9 mg

Vials you'll need

1 × 5 mg

Once you're at the top dose

14 mg / 4 wk · 2.8 vials

Where this plan came from

Built from this peptide's dose range

Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — LL-37

worked out for your mix

Level	Dose	How Often	How Many mL	Draw To	Doses In Vial
Low reported	100 mcg	1× daily	0.06 mL	6 u	50 doses
Mid reported	250 mcg	1× daily	0.15 mL	15 u	20 doses
Upper	500 mcg	1× daily	0.3 mL	30 u	10 doses

Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About LL-37

Immune & Anti-microbial

Also known as

Cathelicidin antimicrobial peptide, hCAP-18 fragment

Class

Immune & Anti-microbial

Route

Subcutaneous

Half-life

Short

Evidence tier

Preclinical

The sole human cathelicidin-derived antimicrobial peptide. Well characterised in immunology literature for direct antimicrobial and immunomodulatory activity; also implicated in rosacea and psoriasis pathology, which cuts against naive "more is better" reasoning.

Buy LL-37

Research Equipment

SyringesU-100 insulin · 1 mL · 29–31G

Alcohol wipes70% isopropyl prep pads

Serum base — for topical mixesHyaluronic acid serum for mixing peptides into a serum

Electric cooler caseTSA-approved travel cooler — keeps mixed vials at fridge temperature

Storage caseHard carry case for vials

Paid affiliate links.

Common Questions — LL-37

How much bacteriostatic water do I add to a 5 mg vial of LL-37?

Adding 3 mL of bacteriostatic water to a 5 mg vial gives 1.67 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of LL-37 is used in research?

Published and reported figures for LL-37 run from 100 mcg to 500 mcg, typically 1× daily. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 100 mcg dose of LL-37?

At 1.67 mg/mL, a 100 mcg dose is 6 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 50 doses.

How strong is the evidence behind these LL-37 doses?

LL-37 is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Where These Numbers Come From

Preclinical — Preclinical and in-vitro data only — no human dosing trials

The human antimicrobial peptide LL-37 — structure and function Dürr UHN, Sudheendra US, Ramamoorthy A. Biochimica et Biophysica Acta, 2006

Standard structural and mechanistic reference.

Find on PubMed ↗

Cathelicidin LL-37 in rosacea and inflammatory skin disease Yamasaki K, Gallo RL. Journal of Dermatological Science, 2007

Documents the pathological side of elevated LL-37 — essential context.

Find on PubMed ↗

Newest Studies — —

—

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

LL-37 Dosage & Reconstitution